Protein HESylation for half-life extension: Synthesis, characterization and pharmacokinetics of HESylated anakinra

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 87, Issue 2, 2014, Pages 378-385

  Liebner, Robert ^a   Mathaes, Roman ^a   Meyer, Martin ^b   Hey, Thomas ^b   Winter, Gerhard ^a   Besheer, Ahmed ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Fresenius Kabi Deutschland GmbH   (Germany)

Author keywords

Anakinra; Binding affinity; HESylation ; Microcalorimetry; Microscale thermophoresis (MST); Pharmacokinetics

Indexed keywords

HETASTARCH; PROPIONALDEHYDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ALDEHYDE; ANTIINFLAMMATORY AGENT; HETASTARCH DERIVATIVE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

AMINATION; ANALYTIC METHOD; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SYNTHESIS; GEL PERMEATION CHROMATOGRAPHY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; MALE; MICROCALORIMETRY; MICROSCALE THERMOPHORESIS; MOLECULAR SIZE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN HESYLATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; RAT; SINGLE DRUG DOSE; SURFACE PLASMON RESONANCE; ANIMAL; CALORIMETRY; GEL CHROMATOGRAPHY; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; LIGHT; MEDICINAL CHEMISTRY; MOLECULAR WEIGHT; PARTICLE SIZE; PHARMACEUTICS; PROCEDURES; RADIATION SCATTERING; SYNTHESIS; WISTAR RAT;

ALDEHYDES; AMINATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; AREA UNDER CURVE; CALORIMETRY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GEL; HALF-LIFE; HYDROXYETHYL STARCH DERIVATIVES; INJECTIONS, INTRAVENOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LIGHT; MALE; MOLECULAR WEIGHT; PARTICLE SIZE; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; RATS, WISTAR; SCATTERING, RADIATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PLASMON RESONANCE; TECHNOLOGY, PHARMACEUTICAL;

EID: 84902367879     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.03.010     Document Type: Article

References (60)

1. B. Leader, Q.J. Baca, and D.E. Golan Protein therapeutics: a summary and pharmacological classification Nat. Rev. Drug Discov. 7 2008 21 39
2. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discov. 2 2003 214 221
3. A. Abuchowski, J.R. McCoy, N.C. Palczuk, E.T. van, and F.F. Davis Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase J. Biol. Chem. 252 1977 3582 3586
4. A. Abuchowski, E.T. van, N.C. Palczuk, and F.F. Davis Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol J. Biol. Chem. 252 1977 3578 3581
5. P. Bailon, and C.Y. Won PEG-modified biopharmaceuticals Expert Opin. Drug Deliv. 6 2009 1 16
6. F.M. Veronese, and G. Pasut PEGylation, successful approach to drug delivery Drug Discov. Today 10 2005 1451 1458
7. R. Webster, V. Elliott, B.K. Park, D. Walker, M. Hankin, and P. Taupin PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals F.M. Veronese, PEGylated Protein Drugs: Basic Science and Clinical Applications 2009 Birkhäuser Verlag Basel, Switzerland 127 146
8. M.A. Young, A. Malavalli, N. Winslow, K.D. Vandegriff, and R.M. Winslow Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys Transl. Res. 149 2007 333 342
9. A. Bendele, J. Seely, C. Richey, G. Sennello, and G. Shopp Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins Toxicol. Sci. 42 1998 152 157
10. R.E. Kontermann Strategies to extend plasma half-lives of recombinant antibodies BioDrugs 23 2009 93 109
11. R.E. Kontermann Strategies for extended serum half-life of protein therapeutics Curr. Opin. Biotechnol. 22 2011 868 876
12. T. Hey, H. Knoller, and P. Vorstheim Half-life extension through HESylation® R. Kontermann, Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives 2012 Wiley-VCH Verlag Gmbh & Co. KGaA Weinheim, Germany 117 140
13. A. Besheer, G. Hause, J. Kressler, and K. Mäder Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles Biomacromolecules 8 2007 359 367
14. A. Besheer, T.C. Hertel, J. Kressler, K. Mäder, and M. Pietzsch Enzymatically catalyzed HES conjugation using microbial transglutaminase: proof of feasibility J. Pharm. Sci. 98 2009 4420 4428
15. M. Noga, D. Edinger, R. Kläger, S.V. Wegner, J.P. Spatz, E. Wagner, G. Winter, and A. Besheer The effect of molar mass and degree of hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-coated polyplexes Biomaterials 34 2013 2530 2538
16. D. Burger, and J.M. Dayer IL-1Ra J.J. Oppenheim, M. Feldmann, Cytokine Reference 2012 Academic Press 319 336
17. A.A. Raibekas, E.J. Bures, C.C. Siska, T. Kohno, R.F. Latypov, and B.A. Kerwin Anion binding and controlled aggregation of human interleukin-1 receptor antagonist Biochemistry 44 2005 9871 9879
18. W.-M. Kulicke, U. Kaiser, D. Schwengers, and R. Lemmes Measurements of the refractive index increment on hydroxyethyl starch as a basis for absolute molecular weight determinations Starch - Stärke 43 1991 392 396
19. Y. Zhang, M. Huo, J. Zhou, and S. Xie PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel Comput. Meth. Prog. Biomed. 99 2010 9
20. B.S. Chang, R.M. Beauvais, T. Arakawa, L.O. Narhi, A. Dong, D.I. Aparisio, and J.F. Carpenter Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution Biophys. J. 71 1996 3399 3406
21. Y. Zhang, S. Roy, L.S. Jones, S. Krishnan, B.A. Kerwin, B.S. Chang, M.C. Manning, T.W. Randolph, and J.F. Carpenter Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution J. Pharm. Sci. 93 2004 3076 3089
22. A. Besheer, R. Liebner, M. Meyer, G. Winter, Challenges for PEGylated proteins and alternative half-life extension technologies based on biodegradable polymers, in: C. Scholz, J. Kressler (Eds.), Tailored Polymer Architectures for Pharmaceutical and Biomedical Applications, 2013, pp. 215-233.
23. R.P. Garay, and J.P. Labaune Immunogenicity of polyethylene glycol (PEG) Open Conf. Proc. J. 2 2011 104 107
24. G. Gregoriadis, A. Fernandes, M. Mital, and B. McCormack Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics Cell Mol. Life Sci. 57 2000 1964 1969
25. G. Gregoriadis, S. Jain, I. Papaioannou, and P. Laing Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids Int. J. Pharm. 300 2005 125 130
26. V. Schellenberger, C.W. Wang, N.C. Geething, B.J. Spink, A. Campbell, W. To, M.D. Scholle, Y. Yin, Y. Yao, O. Bogin, J.L. Cleland, J. Silverman, and W.P. Stemmer A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner Nat. Biotechnol. 27 2009 1186 1190
27. N.C. Geething, W. To, B.J. Spink, M.D. Scholle, C.W. Wang, Y. Yin, Y. Yao, V. Schellenberger, J.L. Cleland, W.P. Stemmer, and J. Silverman Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose PLoS One 5 2010 e10175
28. M. Schlapschy, U. Binder, C. Börger, I. Theobald, K. Wachinger, S. Kisling, D. Haller, and A. Skerra PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins Prot. Eng. Des. Sel. 2013
29. A. Besheer, Nanomedicines Based on Modified Hydroxyethyl Starch: From Synthesis to In Vivo Evaluation, Ph.D. Thesis, Martin-Luther-Universität, Halle-Wittenberg, 2009.
30. C. Jungheinrich, and T.A. Neff Pharmacokinetics of hydroxyethyl starch Clin. Pharmacok. 44 2005 681 699
31. P.Z. Yu, D. Qin, G.H. Qin, B. Fan, G.H. Ma, and Z.G. Su PEGylation of rhIL-1RA increased its solution stability at room temperature Process Biochem. 44 2009 1340 1345
32. P.Z. Yu, C.Y. Zheng, J. Chen, G.F. Zhang, Y.D. Liu, X.Y. Suo, G.C. Zhang, and Z.G. Su Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist Bioorg. Med. Chem. 15 2007 5396 5405
33. O.B. Kinstler, D.N. Brems, S.L. Lauren, A.G. Paige, J.B. Hamburger, and M.J. Treuheit Characterization and stability of N-terminally PEGylated rhG-CSF Pharm. Res. 13 1996 996 1002
34. H. Lee, I.H. Jang, S.H. Ryu, and T.G. Park N-terminal site-specific mono-PEGylation of epidermal growth factor Pharm. Res. 20 2003 818 825
35. O. Kinstler, G. Molineux, M. Treuheit, D. Ladd, and C. Gegg Mono-N-terminal poly(ethylene glycol)-protein conjugates Adv. Drug Deliv. Rev. 54 2002 477 485
36. C. Kessler, A. Greindl, B. Breuer, U. Haberl, A. Rybka, M. Emgenbroich, H.G. Frank, and A.J. Potgens Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities Cytokine 57 2012 226 237
37. A. Greindl, C. Kessler, B. Breuer, U. Haberl, A. Rybka, M. Emgenbroich, A.J. Potgens, and H.G. Frank AGEM400(HES), a novel erythropoietin mimetic peptide conjugated to hydroxyethyl starch with excellent in vitro efficacy Open Hemat. J. 4 2010 1 14
38. C.J. Fee Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules Biotechnol. Bioeng. 98 2007 725 731
39. R.S. Rajan, T. Li, M. Aras, C. Sloey, W. Sutherland, H. Arai, R. Briddell, O. Kinstler, A.M. Lueras, Y. Zhang, H. Yeghnazar, M. Treuheit, and D.N. Brems Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study Protein Sci. 15 2006 1063 1075
40. B.A. Luxon, M. Grace, D. Brassard, and R. Bordens Pegylated interferons for the treatment of chronic hepatitis C infection Clin. Ther. 24 2002 1363 1383
41. P. Bailon, and W. Berthold Polyethylene glycol-conjugated pharmaceutical proteins Pharm. Sci. Technol. Today 1 1998 352 356
42. P. Stigsnaes, S. Frokjaer, S. Bjerregaard, M. van de Weert, P. Kingshott, and E.H. Moeller Characterisation and physical stability of PEGylated glucagon Int. J. Pharm. 330 2007 89 98
43. P. Yu, G. Zhang, J. Bi, X. Lu, Y. Wang, and Z. Su Facile purification of mono-PEGylated interleukin-1 receptor antagonist and its characterization with multi-angle laser light scattering Process Biochem. 42 2007 971 977
44. D. Shental-Bechor, and Y. Levy Folding of glycoproteins: toward understanding the biophysics of the glycosylation code Curr. Opin. Str. Biol. 19 2009 524 533
45. T. Palm, R. Esfandiary, and R. Gandhi The effect of PEGylation on the stability of small therapeutic proteins Pharm. Dev. Technol. 16 2011 441 448
46. C. Dhalluin, A. Ross, L.-A. Leuthold, S. Foser, B. Gsell, F. Müller, and H. Senn Structural and biophysical characterization of the 40 kDa PEG-Interferon-α2a and its individual positional isomers Bioconjugate Chem. 16 2005 504 517
47. J.A. Rodriguez-Martinez, R.J. Sola, B. Castillo, H.R. Cintron-Colon, I. Rivera-Rivera, G. Barletta, and K. Griebenow Stabilization of α-chymotrypsin upon PEGylation correlates with reduced structural dynamics Biotechnol. Bioeng. 101 2008 1142 1149
48. Y. Nie, X. Zhang, X. Wang, and J. Chen Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin Bioconjugate Chem. 17 2006 995 999
49. M. Gonnelli, and G.B. Strambini No effect of covalently linked poly(ethylene glycol) chains on protein internal dynamics Biochim. Biophys. Acta 1794 2009 569 576
50. B. Plesner, C.J. Fee, P. Westh, and A.D. Nielsen Effects of PEG size on structure, function and stability of PEGylated BSA Eur. J. Pharm. Biopharm. 79 2011 399 405
51. C.S. Fishburn The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics J. Pharm. Sci. 97 2008 4167 4183
52. C.J. Wienken, P. Baaske, U. Rothbauer, D. Braun, and S. Duhr Protein-binding assays in biological liquids using microscale thermophoresis Nat. Commun. 1 2010 100
53. S. Duhr, and D. Braun Why molecules move along a temperature gradient Proc. Natl. Acad. Sci. USA 103 2006 19678 19682
54. M. Jerabek-Willemsen, C.J. Wienken, D. Braun, P. Baaske, and S. Duhr Molecular interaction studies using microscale thermophoresis Assay Drug Dev. Technol. 9 2011 342 353
55. M. Malyak, J.M. Guthridge, K.R. Hance, S.K. Dower, J.H. Freed, and W.P. Arend Characterization of a low molecular weight isoform of IL-1 receptor antagonist J. Immunol. 161 1998 1997 2003
56. M.F. Shamji, H. Betre, V.B. Kraus, J. Chen, A. Chilkoti, R. Pichika, K. Masuda, and L.A. Setton Development and characterization of a fusion protein between thermally responsive elastin like polypeptide and interleukin-1 receptor antagonist Arthritis Rheum. 56 2011 3650 3661
57. S. Kubetzko, C.A. Sarkar, and A. Plückthun Protein PEGylation decreases observed target association rates via a dual blocking mechanism Mol. Pharm. 68 2005 1439 1454
58. M.C. Jecklin, S. Schauer, C.E. Dumelin, and R. Zenobi Label-free determination of protein-ligand binding constants using mass spectrometry and validation using surface plasmon resonance and isothermal titration calorimetry J. Mol. Recogn. 22 2009 319 329
59. K.H. Pearce Jr., B.C. Cunningham, G. Fuh, T. Teeri, and J.A. Wells Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity Biochemistry 38 1999 81 89
60. J. Hakimi, P. Kilian, P. Rosen, Polyethylene Glycol Protein Conjugates, 1992 EP 0510356A1.